pharmaphorum| News & views on pharma and biotech’s evolving future

R&D

Interview at LSX 2026 with Alexander Gebauer

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

News

EMA seeks input on virtual alternative to animal test

EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.

R&D

The trust gap: GLP-1s and the new information economy of obe...

R&D

Cancer patient in hospital bed speaking with doctor

Human behaviour in cancer screening trials: A variable that ...

Behavioural phenomena are particularly consequential in screening and prevention research in oncology.

News

Agios' chief medical officer, Sarah Gheuens

Agios mulls early FDA filing for sickle cell therapy

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

Featured Content

R&D

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

R&D

The trust gap: GLP-1s and the new information economy of obe...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Digital

BIO-Europe Spring podcast with Kashif Sadiq

Creating what nature has not from AI and computational molec...

Kashif Sadiq, founder and CEO of DenovAI Biotech discusses harnessing the power of artificial intelligence and computational molecular biophysics.

R&D

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

Sales & Marketing

Sponsored

What HCPs Say Pharma Gets Wrong About Survey Research

Most market researchers already know the standard rules: keep surveys concise, write clear questions, and reduce unnecessary respondent burden.

Newsletters and Deep Dive
digital magazine

Latest News

News

EMA seeks input on virtual alternative to animal test

EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.

News

Agios mulls early FDA filing for sickle cell therapy

Agios is planning to file its sickle cell disease candidate mitapivat with the FDA under the accelerated pathway within the next few months.

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

News

NHS to offer Wegovy to a million more people in England

The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.

Views & Analysis

R&D

LSX2026: On a therapeutic vision for ocular disease, with Al...

Alexander Gebauer, co-founder & executive chairman of Galimedix Therapeutics, discusses transforming treatment of major neurodegenerative eye diseases

R&D

Human behaviour in cancer screening trials: A variable that ...

Behavioural phenomena are particularly consequential in screening and prevention research in oncology.

R&D

Test tubes being prepared for flow cytometry

Overcoming 6 data management challenges in flow cytometry

Large-scale flow cytometry delivers critical biological insight by enabling multidimensional analysis of individual cells, making it fundamental to medical research.

Patients